XenoPort to Present at the Cowen and Company 36th Annual Health Care Conference
March 01 2016 - 1:28PM
Business Wire
XenoPort, Inc. (Nasdaq: XNPT) announced today that it will
provide access via the World Wide Web to its presentation at the
2016 Cowen and Company 36th Annual Health Care Conference. The live
presentation will occur at 5:40 a.m. Pacific Time (8:40 a.m.
Eastern Time) on Wednesday, March 9, 2016. A replay of the
presentation will also be available.
To access the live presentation via the Web, please go to
www.XenoPort.com. Please connect to the Web site at least 15
minutes prior to the live presentation to ensure adequate time for
any software downloads that may be necessary to listen to the
Webcast.
A replay of the Webcast can be accessed for a minimum of one
month and will be available approximately 24 hours after the live
presentation.
About XenoPort
XenoPort, Inc. is a biopharmaceutical company focused on
commercializing HORIZANT® (gabapentin enacarbil) Extended-Release
Tablets in the United States. XenoPort has entered into a clinical
trial agreement with the National Institute on Alcohol Abuse and
Alcoholism (NIAAA) under which the NIAAA has initiated a clinical
trial evaluating gabapentin enacarbil as a potential treatment for
patients with alcohol use disorder. REGNITE® (gabapentin enacarbil)
Extended-Release Tablets is being marketed in Japan by Astellas
Pharma Inc. XenoPort has granted exclusive world-wide rights for
the development and commercialization of its clinical-stage oral
product candidate, arbaclofen placarbil, to Indivior UK Ltd. for
all indications. XenoPort’s other product candidates include
XP23829, a novel fumaric acid ester prodrug that is a potential
treatment for patients with moderate-to-severe chronic plaque-type
psoriasis or patients with relapsing forms of multiple sclerosis,
and XP21279, a prodrug of levodopa that is a potential treatment
for patients with idiopathic Parkinson's disease.
To learn more about XenoPort, please visit the website at
www.XenoPort.com.
HORIZANT, REGNITE and XENOPORT are registered trademarks of
XenoPort, Inc.
XNPT2G
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160301006783/en/
XenoPort, Inc.Jackie Cossmon, 408-616-7220ir@XenoPort.com
Xenoport, Inc. (NASDAQ:XNPT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Xenoport, Inc. (NASDAQ:XNPT)
Historical Stock Chart
From Apr 2023 to Apr 2024